Skip to main navigation
Skip to search
Skip to main content
Sefako Makgatho Health Sciences University Home
Home
Profiles
Departments
Research output
Activities
Search by expertise, name or affiliation
Rifaximin in non-alcoholic steatohepatitis: An open-label pilot study
Jeremy F.L. Cobbold
*
, Stephen Atkinson
, Julian R. Marchesi
, Ann Smith
, Sann N. Wai
, Julie Stove
, Fariba Shojaee-Moradie
, Nicola Jackson
, A. Margot Umpleby
, Julie Fitzpatrick
,
E. Louise Thomas
, Jimmy D. Bell
, Elaine Holmes
, Simon D. Taylor-Robinson
, Robert D. Goldin
, Michael S. Yee
, Quentin M. Anstee
, Mark R. Thursz
*
Corresponding author for this work
Research output
:
Contribution to journal
›
Article
›
peer-review
47
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Rifaximin in non-alcoholic steatohepatitis: An open-label pilot study'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Nonalcoholic Steatohepatitis
100%
Rifaximin
100%
Diabetes
28%
Alanine Aminotransferase
28%
Lipid Content
28%
Hepatic Lipid
28%
Hepatic Insulin Sensitivity
28%
Oral Hypoglycemic Agents
14%
Metabolic Profiling
14%
Beneficial Effects
14%
Insulin Sensitivity
14%
Median Range
14%
Twice Daily
14%
Observation Period
14%
Glucose Uptake
14%
Relative Abundance
14%
Serum Alanine Aminotransferase
14%
Steatosis
14%
Hippurate
14%
Homeostatic Model
14%
Insulin Resistance Index
14%
Fecal Microbiota
14%
Gut Microbiota Modulation
14%
Downstream Effects
14%
Biopsy-proven
14%
Elevated Aminotransferases
14%
Hepatic Inflammation
14%
Peripheral Insulin Sensitivity
14%
Gut Dysbiosis
14%
Hyperinsulinemic-euglycemic Clamp
14%
Medicine and Dentistry
Nonalcoholic Fatty Liver
100%
Rifaximin
100%
Alanine Aminotransferase
42%
Insulin Sensitivity
42%
Diabetes
28%
Urinary System
28%
Antidiabetic Agent
14%
Drug Therapy
14%
Gut
14%
Insulin Resistance
14%
Glucose Uptake
14%
Homeostasis
14%
Gut Microbiota
14%
Biopsy Technique
14%
Steatosis
14%
Hippuric Acid
14%
Transaminase
14%
Resistance Index
14%
Dysbiosis
14%
Pharmacology, Toxicology and Pharmaceutical Science
Nonalcoholic Fatty Liver
100%
Rifaximin
100%
Alanine Aminotransferase
42%
Antidiabetic Agent
14%
Inflammation
14%
Intestine Flora
14%
Insulin Resistance
14%
Aminotransferase
14%
Steatosis
14%
Hippuric Acid
14%
Dysbiosis
14%
Feces microflora
14%